Evercore ISI Group Maintains Outperform on Insmed, Lowers Price Target to $160

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and lowers the price target from $162 to $160.